ANXA2 and metabolic dysfunction-associated steatotic liver disease: Significant increase of ANXA2 in hepatic expression with NAFLD and NASH, linked to 14-3-3 proteins and associated with poor clinical outcome [105]Hepatic ANXA5 expression correlates with disease progression from NAFLD to NASH [106]